Heart failure as a substrate and trigger for ventricular tachycardia.

Area of Science:

• Cardiology
• Electrophysiology
• Heart Failure Research

Background:

• Heart failure (HF) affects millions, increasing morbidity and mortality.
• Ventricular tachyarrhythmias (VAs) are common complications of HF.
• HF pathophysiology involves complex changes predisposing to arrhythmias.

Purpose of the Study:

• To review mechanisms of arrhythmogenesis in HF.
• To examine the impact of HF therapies on VAs.
• To discuss telemonitoring and LVAD effects on VAs.

Main Methods:

• Literature review of HF pathophysiology and arrhythmia mechanisms.
• Analysis of clinical trial data on HF medications and devices.
• Review of studies on cardiac resynchronization therapy (CRT) and LVADs.

Main Results:

• HF-related changes like hypertrophy, fibrosis, and calcium handling promote VAs.
• Beta-blockers and sacubitril/valsartan reduce mortality and sudden cardiac death (SCD).
• ICDs reduce SCD but may increase overall mortality if shocks occur; prophylactic ICDs have nuanced effects.

Conclusions:

• HF therapies have varied impacts on VAs and overall mortality.
• CRT, telemonitoring, and LVADs play roles in managing VAs in HF.
• Further research is needed to optimize VA prevention and management in HF.